Canagliflozin may not be good for the heart, FDA says


Canagliflozin (Janssen Research & Development), developed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, raised the level of bad cholesterol in patients during clinical trials and may post heart risks, according to FDA and reported by Reuters.


Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.